ALLMedicine™ Ocular Hypertension Center

May 3rd, 2021 - In POAG, elevated IOP remains the major risk factor in irreversible vision loss. Increased TGFβ2 expression in POAG aqueous humor and in the trabecular meshwork (TM) amplifies extracellular matrix (ECM) deposition and reduces ECM turnover in the T...

Apr 23rd, 2021 - To compare the tolerability and efficacy of a preservative-containing latanoprost (PCL) to a preservative-free formulation of latanoprost (PFL) in patients with open-angle glaucoma or ocular hypertension. A pooled analysis was performed of data fr...

Apr 22nd, 2021 - Reducing intraocular pressure (IOP), the only modifiable risk factor for open-angle glaucoma (OAG), is important for the preservation of vision and slowing of disease progression. Preservative-free tafluprost (0.0015%)/timolol (0.5%) fixed combina...

Apr 16th, 2021 - Background: Y-27632 is a potent ophthalmic drug for the treatment of ocular hypertension, a globally prevalent eye disease. However, the sustained delivery of Y-27632 by a therapeutic carrier to lesion sites located in the inner segments of the ey...

Apr 15th, 2021 - Ocular hypertension is an important risk factor for the development of primary open-angle glaucoma (POAG). Data from long-term follow-up can be used to inform the management of patients with ocular hypertension. To determine the cumulative inciden...

May 3rd, 2021 - In POAG, elevated IOP remains the major risk factor in irreversible vision loss. Increased TGFβ2 expression in POAG aqueous humor and in the trabecular meshwork (TM) amplifies extracellular matrix (ECM) deposition and reduces ECM turnover in the T...

Apr 27th, 2021 - Takeaway Preservative-free tafluprost (0.0015%)/timolol (0.5%) fixed combination (PF-Taf-T-FC) was effective in reducing intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), inadequately controlled on...

Apr 23rd, 2021 - To compare the tolerability and efficacy of a preservative-containing latanoprost (PCL) to a preservative-free formulation of latanoprost (PFL) in patients with open-angle glaucoma or ocular hypertension. A pooled analysis was performed of data fr...

Apr 22nd, 2021 - Reducing intraocular pressure (IOP), the only modifiable risk factor for open-angle glaucoma (OAG), is important for the preservation of vision and slowing of disease progression. Preservative-free tafluprost (0.0015%)/timolol (0.5%) fixed combina...

Apr 16th, 2021 - Background: Y-27632 is a potent ophthalmic drug for the treatment of ocular hypertension, a globally prevalent eye disease. However, the sustained delivery of Y-27632 by a therapeutic carrier to lesion sites located in the inner segments of the ey...

Apr 27th, 2021 - Takeaway Preservative-free tafluprost (0.0015%)/timolol (0.5%) fixed combination (PF-Taf-T-FC) was effective in reducing intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), inadequately controlled on...

Apr 14th, 2021 - Only about a quarter of patients with ocular hypertension lose peripheral vision, so clinicians should not recommend treatment to everyone with this condition, a long-term study suggests. The 20-year results of the phase 3 Ocular Hypertension Stud...

Dec 8th, 2020 - With the ongoing pandemic, ophthalmologists continue to search for new ways to reduce patient visits and possible virus exposure without sacrificing outcomes. Not surprisingly, monitoring and adjusting eye drop treatments to lower intraocular pres...

Nov 15th, 2020 - The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the fixed-dose combination of latanoprost and netarsudil (Roclanda). The ophthalmic solution is indicated to decrease elevate...

Apr 28th, 2020 - NEW YORK (Reuters Health) - Patients with uveitic glaucoma (UG) whose intraocular pressure (IOP) is under control and do not have uveitis recurrence may benefit from ocular hypotensive treatment washout, new findings show. Stopping hypotensive tre...